M. Smith
Royal Hallamshire Hospital
5 Papers
1 Citations
M. Smith is an academic researcher from Royal Hallamshire Hospital. The author has contributed to research in topics: Medicine & Immunology. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
AB0463 A review of the outcomes of women with rheumatoid arthritis (RA) treated with biologic agents attending the sheffield combined obstetrics and rheumatology clinic 2002 to 2013
TL;DR: A group of patients is small, but the outcomes are comparable to those of women with RA, and the next step in this project is to review the data from more recent pregnancies to determine whether more prolonged use of biologics improves disease control and in turn foetal and maternal outcomes.
3
Op0109 single-cell rna-seq reveals differences in metabolic pathways of myeloid cells in the progression of sle
Aleksandra Bylińska,M. Smith,Kaitlin K. Thomas,Carla J. Guthridge,Samantha Slight-Webb,Susan R. Macwana,J. A. James,J. Guthridge +7 more
TL;DR: Slight-Webb et al. as mentioned in this paper used a microfluidic flow cytometer to identify 9 distinct myeloid clusters (Classical, Non-classical, Intermediate, CCR4+ monocytes) with a community detection algorithm and visualized with Uniform Manifold approximation projection (UMAP).
Pos1155 impact of hydroxychloroquine on interferon pathway expression of sle phenotypic subsets in the absence of background medications
C.Scott Mowery,M. Smith,Konstantinos Thomas,Susan R. Macwana,Wade DeJager,Stan Kamp,B. Parrish,Cristina Arriens,Teresa Aberle,Joan T. Merrill,J. Guthridge,J. A. James +11 more
TL;DR: Guthridge et al. as mentioned in this paper compared the effect of hydroxychloroquine (HCQ) on interferon pathway activation in SLE patients with discrete immune phenotypes without corticosteroids or any other SLE treatments.
1
Pos0296 gene expression in sle patients, dominated by unique b cell profiles, distinguishes those with clinical improvement from abatacept
Konstantinos Thomas,M. Smith,Carla J. Guthridge,Nicolas Dominguez,Susan R. Macwana,Wade DeJager,P. Shafer,Stan Kamp,Aikaterini Thanou,Cristina Arriens,J. T. Merrill,J. A. James,J. Guthridge +12 more
TL;DR: Merrill et al. as discussed by the authors used data and samples collected from previous clinical trials to identify pathways of Systemic Lupus Erythematosus (SLE) and potential biomarkers which predict clinical response to ABA.
Pos1154 pre-treatment differentially expressed metagenes characterize systemic lupus patients who subsequently achieve clinical response to belimumab
J. T. Merrill,M. Smith,Koruth Thomas,Carla J. Guthridge,Nicolas Dominguez,Susan R. Macwana,Wade DeJager,Stan Kamp,Cristina Arriens,B. Parrish,J. A. James +10 more
TL;DR: Merrill et al. as discussed by the authors conducted a prospective open-label study of 24 systemic lupus patients with active but non-organ threatening disease, who were required to withdraw other immune suppressants (only antimalarials or low dose steroids allowed).